title: Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?
authors.forename: B M
authors.initials: BM
authors.lastname: Frost
authors.forename: G
authors.initials: G
authors.lastname: Gustafsson
authors.forename: R
authors.initials: R
authors.lastname: Larsson
authors.forename: P
authors.initials: P
authors.lastname: Nygren
authors.forename: G
authors.initials: G
authors.lastname: Lönnerholm
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D001752:Blast Crisis; D002470:Cell Survival / Q000187:drug effects*; D002648:Child; D003561:Cytarabine / Q000633:toxicity; D003907:Dexamethasone / Q000633:toxicity; D004314:Down Syndrome / Q000150:complications*; D004317:Doxorubicin / Q000633:toxicity; D005047:Etoposide / Q000633:toxicity; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology; D013866:Thioguanine / Q000633:toxicity; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine; D005047:Etoposide; D003907:Dexamethasone; D004317:Doxorubicin; D013866:Thioguanine